Akari Therapeutics reports Q3 EPS (0c), two est. (12c)
"We are excited about the positive clinical data we are accumulating in patients treated with nomacopan across our target rare disease indications. The rapid and sustained clinical clinical improvement combined with the positive long-term safety profile we have observed in patients, helps to offer further validation of nomacopan's unique method of action as an inhibitor of both the complement and leukotriene pathways," said Clive Richardson, Chief Executive Officer of Akari Therapeutics. "We look forward to further progress across both our topical and subcutaneous clinical programs in 2020 as we look to drive nomacopan through the clinic and towards helping patients afflicted by these rare and debilitating inflammatory conditions. In addition, we seek to partner those programs in which a joint development approach can produce a faster outcome."